Publications, Pharmaceutical

Confirming bioequivalence for a generic tiotropium dry powder inhalers

Pharmacokinetic (PK) profiling is a central strategy for the demonstration of bioequivalence in generic dry powder inhaler development.

This paper describes a study in which in vitro testing under clinically relevant conditions, an in silico regional deposition model and a physiologically-based PK simulation model were used together to compare Test and Reference tiotropium products. In vitro testing detected significant batch to batch variability in the Reference product while in silico and PK data, in combination, highlighted the potential for variability in peripheral dose deposition to impact PK profile. The developed in silico model, once validated, has considerable potential to elucidate correlations between in vitro and in vivo data and help generic developers to establish and demonstrate robust bioequivalence.

Download Publication
25 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

3 Jul 2023

Leachables Assessment: New pMDI with Low-GWP Propellants

Publications, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
3 Jul 2023

Performance of Low-GWP Propellants in pMDIs: Filling and Dose Evaluation

Publications, Pharmaceutical, Product Solutions, Sustainability, Device Innovations, Market Insights

Read More
3 Jul 2023

Orally Inhaled Drug products; Bioequivalence Models

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
10 May 2023

Navigating the Development for Orally Inhaled and Nasal Drug Products

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 17
Back To Top